Cargando…

In Vitro Activity of Auranofin in Combination With Aztreonam-Avibactam Against Metallo-β-lactamase (MBL)-Producing Enterobacterales

OBJECTIVES: To assess the efficacy of aztreonam-avibactam-auranofin (ATM-AVI-AUR) against a collection of 88 carbapenemase-producing Enterobacterales (CPE) clinical isolates and 6 in vitro selected ATM-AVI-resistant CPE with CMY-16 Tyr150Ser and Asn346His mutants or transformants. METHODS: MICs of i...

Descripción completa

Detalles Bibliográficos
Autores principales: Wang, Wen, Huang, Shifeng, Zou, Chunhong, Ding, Yanhui, Wang, Huijuan, Pu, Shuli, Liao, Yunfeng, Du, Hong, Wang, Deqiang, Chen, Liang, Niu, Siqiang
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Frontiers Media S.A. 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581557/
https://www.ncbi.nlm.nih.gov/pubmed/34778107
http://dx.doi.org/10.3389/fcimb.2021.755763
_version_ 1784596831960825856
author Wang, Wen
Huang, Shifeng
Zou, Chunhong
Ding, Yanhui
Wang, Huijuan
Pu, Shuli
Liao, Yunfeng
Du, Hong
Wang, Deqiang
Chen, Liang
Niu, Siqiang
author_facet Wang, Wen
Huang, Shifeng
Zou, Chunhong
Ding, Yanhui
Wang, Huijuan
Pu, Shuli
Liao, Yunfeng
Du, Hong
Wang, Deqiang
Chen, Liang
Niu, Siqiang
author_sort Wang, Wen
collection PubMed
description OBJECTIVES: To assess the efficacy of aztreonam-avibactam-auranofin (ATM-AVI-AUR) against a collection of 88 carbapenemase-producing Enterobacterales (CPE) clinical isolates and 6 in vitro selected ATM-AVI-resistant CPE with CMY-16 Tyr150Ser and Asn346His mutants or transformants. METHODS: MICs of imipenem, ceftazidime-avibact8am (CAZ-AVI), ATM-AVI, CAZ-AVI-AUR and ATM-AVI-AUR were determined via the broth microdilution method. Genetic background and carbapenemase genes were determined by PCR and Sanger sequencing. RESULTS: AUR alone showed little antibacterial activity with AUR MICs were greater than 64 μg/mL for all the 88 clinical CPE isolates. The addition of AUR (16 μg/mL) resulted in an 3-folding dilutions MIC reduction of ATM-AVI MIC(50) (0.5 to 0.0625 μg/mL) and a 2-folding dilutions MIC reduction of MIC(90) (1 to 0.25 μg/mL) against all 88 clinical CPE isolates, respectively. Notably, the reduced ATM-AVI MIC values were mainly found in MBL-producers, and the MIC(50) and MIC(90) reduced by 2-folding dilutions (0.25 to 0.0625 μg/mL) and 3-folding dilutions (2 to 0.25 μg/mL) respectively by AUR among the 51 MBL-producers. By contrast, the addition of AUR did not showed significant effects on ATM-AVI MIC(50) (0.0625 μg/mL) and MIC(90) (0.125 μg/mL) among single KPC-producers. Interestingly, the addition of AUR restored the ATM-AVI susceptibility against the 6 in vitro selected ATM-AVI-resistant CMY-16 Tyr150Ser and Asn346His mutants or transfromants, with the MICs reduced from ≥32 μg/mL (32->256 μg/mL) to ≤8 μg/mL (0.0625-8 μg/mL). CONCLUSIONS: Our results demonstrated that AUR potentiated the activities of CAZ-AVI and ATM-AVI against MBL-producing isolates in vitro. Importantly, AUR restored the ATM-AVI activity against ATM-AVI resistant mutant strains. As a clinically approved drug, AUR might be repurposed in combination with ATM-AVI to treat infections caused by highly resistant MBL-producing Enterobacterales.
format Online
Article
Text
id pubmed-8581557
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Frontiers Media S.A.
record_format MEDLINE/PubMed
spelling pubmed-85815572021-11-12 In Vitro Activity of Auranofin in Combination With Aztreonam-Avibactam Against Metallo-β-lactamase (MBL)-Producing Enterobacterales Wang, Wen Huang, Shifeng Zou, Chunhong Ding, Yanhui Wang, Huijuan Pu, Shuli Liao, Yunfeng Du, Hong Wang, Deqiang Chen, Liang Niu, Siqiang Front Cell Infect Microbiol Cellular and Infection Microbiology OBJECTIVES: To assess the efficacy of aztreonam-avibactam-auranofin (ATM-AVI-AUR) against a collection of 88 carbapenemase-producing Enterobacterales (CPE) clinical isolates and 6 in vitro selected ATM-AVI-resistant CPE with CMY-16 Tyr150Ser and Asn346His mutants or transformants. METHODS: MICs of imipenem, ceftazidime-avibact8am (CAZ-AVI), ATM-AVI, CAZ-AVI-AUR and ATM-AVI-AUR were determined via the broth microdilution method. Genetic background and carbapenemase genes were determined by PCR and Sanger sequencing. RESULTS: AUR alone showed little antibacterial activity with AUR MICs were greater than 64 μg/mL for all the 88 clinical CPE isolates. The addition of AUR (16 μg/mL) resulted in an 3-folding dilutions MIC reduction of ATM-AVI MIC(50) (0.5 to 0.0625 μg/mL) and a 2-folding dilutions MIC reduction of MIC(90) (1 to 0.25 μg/mL) against all 88 clinical CPE isolates, respectively. Notably, the reduced ATM-AVI MIC values were mainly found in MBL-producers, and the MIC(50) and MIC(90) reduced by 2-folding dilutions (0.25 to 0.0625 μg/mL) and 3-folding dilutions (2 to 0.25 μg/mL) respectively by AUR among the 51 MBL-producers. By contrast, the addition of AUR did not showed significant effects on ATM-AVI MIC(50) (0.0625 μg/mL) and MIC(90) (0.125 μg/mL) among single KPC-producers. Interestingly, the addition of AUR restored the ATM-AVI susceptibility against the 6 in vitro selected ATM-AVI-resistant CMY-16 Tyr150Ser and Asn346His mutants or transfromants, with the MICs reduced from ≥32 μg/mL (32->256 μg/mL) to ≤8 μg/mL (0.0625-8 μg/mL). CONCLUSIONS: Our results demonstrated that AUR potentiated the activities of CAZ-AVI and ATM-AVI against MBL-producing isolates in vitro. Importantly, AUR restored the ATM-AVI activity against ATM-AVI resistant mutant strains. As a clinically approved drug, AUR might be repurposed in combination with ATM-AVI to treat infections caused by highly resistant MBL-producing Enterobacterales. Frontiers Media S.A. 2021-10-28 /pmc/articles/PMC8581557/ /pubmed/34778107 http://dx.doi.org/10.3389/fcimb.2021.755763 Text en Copyright © 2021 Wang, Huang, Zou, Ding, Wang, Pu, Liao, Du, Wang, Chen and Niu https://creativecommons.org/licenses/by/4.0/This is an open-access article distributed under the terms of the Creative Commons Attribution License (CC BY). The use, distribution or reproduction in other forums is permitted, provided the original author(s) and the copyright owner(s) are credited and that the original publication in this journal is cited, in accordance with accepted academic practice. No use, distribution or reproduction is permitted which does not comply with these terms.
spellingShingle Cellular and Infection Microbiology
Wang, Wen
Huang, Shifeng
Zou, Chunhong
Ding, Yanhui
Wang, Huijuan
Pu, Shuli
Liao, Yunfeng
Du, Hong
Wang, Deqiang
Chen, Liang
Niu, Siqiang
In Vitro Activity of Auranofin in Combination With Aztreonam-Avibactam Against Metallo-β-lactamase (MBL)-Producing Enterobacterales
title In Vitro Activity of Auranofin in Combination With Aztreonam-Avibactam Against Metallo-β-lactamase (MBL)-Producing Enterobacterales
title_full In Vitro Activity of Auranofin in Combination With Aztreonam-Avibactam Against Metallo-β-lactamase (MBL)-Producing Enterobacterales
title_fullStr In Vitro Activity of Auranofin in Combination With Aztreonam-Avibactam Against Metallo-β-lactamase (MBL)-Producing Enterobacterales
title_full_unstemmed In Vitro Activity of Auranofin in Combination With Aztreonam-Avibactam Against Metallo-β-lactamase (MBL)-Producing Enterobacterales
title_short In Vitro Activity of Auranofin in Combination With Aztreonam-Avibactam Against Metallo-β-lactamase (MBL)-Producing Enterobacterales
title_sort in vitro activity of auranofin in combination with aztreonam-avibactam against metallo-β-lactamase (mbl)-producing enterobacterales
topic Cellular and Infection Microbiology
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8581557/
https://www.ncbi.nlm.nih.gov/pubmed/34778107
http://dx.doi.org/10.3389/fcimb.2021.755763
work_keys_str_mv AT wangwen invitroactivityofauranofinincombinationwithaztreonamavibactamagainstmetalloblactamasemblproducingenterobacterales
AT huangshifeng invitroactivityofauranofinincombinationwithaztreonamavibactamagainstmetalloblactamasemblproducingenterobacterales
AT zouchunhong invitroactivityofauranofinincombinationwithaztreonamavibactamagainstmetalloblactamasemblproducingenterobacterales
AT dingyanhui invitroactivityofauranofinincombinationwithaztreonamavibactamagainstmetalloblactamasemblproducingenterobacterales
AT wanghuijuan invitroactivityofauranofinincombinationwithaztreonamavibactamagainstmetalloblactamasemblproducingenterobacterales
AT pushuli invitroactivityofauranofinincombinationwithaztreonamavibactamagainstmetalloblactamasemblproducingenterobacterales
AT liaoyunfeng invitroactivityofauranofinincombinationwithaztreonamavibactamagainstmetalloblactamasemblproducingenterobacterales
AT duhong invitroactivityofauranofinincombinationwithaztreonamavibactamagainstmetalloblactamasemblproducingenterobacterales
AT wangdeqiang invitroactivityofauranofinincombinationwithaztreonamavibactamagainstmetalloblactamasemblproducingenterobacterales
AT chenliang invitroactivityofauranofinincombinationwithaztreonamavibactamagainstmetalloblactamasemblproducingenterobacterales
AT niusiqiang invitroactivityofauranofinincombinationwithaztreonamavibactamagainstmetalloblactamasemblproducingenterobacterales